2C-C-NBOMe

2C-C-NBOMe

Systematic (IUPAC) name
2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
Clinical data
Pregnancy cat.	?
Legal status	Class C (NZ)
Identifiers
CAS number	1227608-02-7 N
ATC code	?
PubChem	CID 46856354
ChemSpider	24583389 Y
Chemical data
Formula	C18H22ClNO3
Mol. mass	335.83 g/mol
SMILES COc2ccccc2CNCCc(cc1OC)c(OC)cc1Cl
InChI InChI=1S/C18H22ClNO3/c1-21-16-7-5-4-6-14(16)12-20-9-8-13-10-18(23-3)15(19)11-17(13)22-2/h4-7,10-11,20H,8-9,12H2,1-3H3 Y Key:FJFPOGCVVLUYAQ-UHFFFAOYSA-N Y
N (what is this?)  (verify)

2C-C-NBOMe (NBOMe-2C-C, 25C-NBOMe) is a derivative of the phenethylamine hallucinogen 2C-C, which acts as a potent partial agonist for the 5HT_2A receptor, and has been studied in its ¹¹C radiolabelled form as a potential ligand for mapping the distribution of 5-HT_2A receptors in the brain, using positron emission tomography (PET). Anecdotal reports from human users suggest 2C-C-NBOMe to be an active hallucinogen at a dose of as little as 200-500mcg insufflated, making it only slightly less potent than LSD.^{[citation needed]} NBOMes have a diminished absorption rate passing through mucus membranes, but generally remain inactive when taken orally. Buccal, sublingual or insufflated routes of administration are all viable options. Absorption rate buccally and sublingually can be increased when complexed with HPBCD complexing sugar, however the most efficient method is nasal administration, although this shortens the duration while increasing intensity.

History

2C-C-NBOMe has no history of human use prior to 2010 when it first became available online. It was presumably first synthesized in the research laboratory of David E. Nichols at Purdue University. 25C-NBOMe is derived from the psychedelic phenethylamine 2C-C by substitution on the amine with a 2-methoxybenzyl group. 2C-C-NBOMe is a clumpy white powder with a notably bitter and metallic taste. 2C-C-NBOMe has been found on blotter mimics sold as LSD. It was for sale as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and therefore a Class C controlled drug analogue.

See also

• 2CBCB-NBOMe (NBOMe-TCB-2)
• 2CBFly-NBOMe (NBOMe-2CB-Fly)
• 25B-NBOMe (NBOMe-2CB)
• 25I-NBOMe (NBOMe-2CI)
• 2C-TFM-NBOMe (NBOMe-2C-TFM)
• 25I-NBMD (NBMD-2CI)
• 25I-NBOH (NBOH-2CI)
• 25I-NBF (NBF-2CI)
• 5-MeO-NBpBrT